The Role of Intermittent Fasting on Metabolic Syndrome: A Systematic Review and Meta-Analysis.

Intermittent fasting has gained popularity as a dietary intervention to improve metabolic health. Metabolic syndrome may benefit from intermittent fasting by improving weight, cholesterol levels, blood pressure (BP), and glucose control. This study aims to assess the effects of intermittent fasting on weight, BMI, cholesterol levels, BP, and glucose in individuals with metabolic syndrome. This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and included 11 studies examining the effects of intermittent fasting on metabolic syndrome. A comprehensive search of PubMed and Google Scholar identified 6,451 studies, of which 11 met the inclusion criteria. Data on weight, BMI, cholesterol, BP, and glucose levels were extracted, and a random effects meta-analysis was conducted to assess outcomes. Analysis showed significant improvements in weight, with a mean reduction of 3.59 kg (95% CI: -4.59 to -2.59, p < 0.0001) and a decrease in BMI of 1.39 kg/m (95% CI: -1.87 to -0.92, p < 0.0001). Low-density lipoprotein (LDL) cholesterol levels dropped by 56.22 mg/dL (95% CI: -80.14 to -32.29, p < 0.0001), and systolic BP decreased by 5.54 mmHg (95% CI: -7.55 to -3.53, p < 0.0001). However, high-density lipoprotein (HDL) cholesterol showed minimal changes, and glucose levels remained stable. Intermittent fasting led to significant reductions in weight, BMI, LDL cholesterol, and BP, making it a promising non-pharmacological strategy for managing metabolic syndrome. Further research is needed to explore long-term effects and optimal fasting protocols for different populations.